secwatch.observer — SEC 8-K summary
======================================

Issuer:     CV Sciences, Inc. (CVSI)
CIK:        0001510964
Form:       8-K
Filed at:   2026-05-14T20:04:49+00:00
Accession:  0001193125-26-223967
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CV Sciences Q1 revenue down 11.4% to $3.2M; adjusted EBITDA loss narrows to $0.1M
--------------------------------------------------------------------------------

- Revenue $3.2M (down 11.4% YoY); unit sales down 12.2%, partially offset by minor price increases.
- Gross margin improved to 48.9% (from 46.0% YoY); operating loss $0.3M vs prior year operating income due to $0.5M payroll tax reversal.
- Adjusted EBITDA loss of $0.1M vs $0.3M loss in Q1 2025; cash balance $0.3M at quarter end.
- Completed debt restructuring to strengthen financial position; launched EMPOWR plant-based protein/creatine formula.
- New products launched since Jan 2023 contributed 43% of Q1 net revenue; 45 new products introduced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1510964/000119312526223967/0001193125-26-223967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1510964/000119312526223967/cvsi-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-223967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer